Tumor Necrosis Factor Receptor Superfamily Member 9 Pipeline Review, H2 2019
Summary
Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 pipeline Target constitutes close to 55 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 9 Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 Tumor necrosis factor receptor superfamily member 9 TNFRSF9, also known as CD137 is a member of the tumor necrosis factor TNF receptor family. CD137 is expressed by activated T cells but to a larger extent on CD8 than on CD4 T cells. CD137 are involved in the regulation of a wide range of immune activities. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 12, 26 and 7 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Solid Tumor, Colorectal Cancer, NonSmall Cell Lung Cancer, Diffuse Large BCell Lymphoma, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Bladder Cancer, Colon Carcinoma, Follicular Lymphoma, Hematological Tumor, Lung Cancer, Metastatic Breast Cancer, Metastatic Melanoma, NonHodgkin Lymphoma, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, BCell NonHodgkin Lymphoma, Cervical Cancer, Colon Cancer, Endometrial Cancer, Leukemia, Mantle Cell Lymphoma, Metastatic Cancer, Ovarian Cancer, Prostate Cancer, Transitional Cell Carcinoma Urothelial Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Anal Cancer, BCell Chronic Lymphocytic Leukemia, Breast Cancer, Burkitt Lymphoma, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Esophageal Cancer, Gastroesophageal GE Junction Carcinomas, Gliosarcoma, Gynecological Cancer, Hepatocellular Carcinoma, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Kidney Cancer Renal Cell Cancer, Lymphoma, Malignant Mesothelioma, Metastatic Lung Cancer, Multiple Myeloma Kahler Disease, Nasopharyngeal Cancer, Pancreatic Cancer, Primary CNS Lymphoma, Primary Mediastinal BCell Lymphoma, Recurrent Glioblastoma Multiforme GBM, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia CLL, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia CLL, Renal Cell Carcinoma, Secondary CNS Lymphoma, Squamous Cell Carcinoma, Transitional Cell Cancer Urothelial Cell Cancer and TripleNegative Breast Cancer TNBC.
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Scope
The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9
The report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics and enlists all their major and minor projects
The report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 41BB Ligand Receptor or T Cell Antigen 41BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope